These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 25166023)
61. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Nauck MA Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775 [TBL] [Abstract][Full Text] [Related]
62. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Qiu R; Balis D; Xie J; Davies MJ; Desai M; Meininger G Curr Med Res Opin; 2017 Mar; 33(3):553-562. PubMed ID: 27977934 [TBL] [Abstract][Full Text] [Related]
63. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus. Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084 [TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406 [TBL] [Abstract][Full Text] [Related]
65. Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer. Sanyal D; Majumder A; Ghosh S; Pandit K Diabetes Metab Syndr; 2021; 15(1):385-389. PubMed ID: 33548908 [TBL] [Abstract][Full Text] [Related]
66. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Nicolle LE; Capuano G; Fung A; Usiskin K Postgrad Med; 2014 Jan; 126(1):7-17. PubMed ID: 24393747 [TBL] [Abstract][Full Text] [Related]
67. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803 [TBL] [Abstract][Full Text] [Related]
68. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772 [TBL] [Abstract][Full Text] [Related]
69. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus]. Matthaei S Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634 [No Abstract] [Full Text] [Related]
70. Canagliflozin: a novel treatment option for type 2 diabetes. Dietrich E; Powell J; Taylor JR Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921 [TBL] [Abstract][Full Text] [Related]
71. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Polidori D; Mari A; Ferrannini E Diabetologia; 2014 May; 57(5):891-901. PubMed ID: 24585202 [TBL] [Abstract][Full Text] [Related]
72. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial. Kaku K; Isaka H; Toyoshima J; Sakatani T Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047 [TBL] [Abstract][Full Text] [Related]
73. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421 [TBL] [Abstract][Full Text] [Related]
74. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972 [TBL] [Abstract][Full Text] [Related]
75. Renal effects of canagliflozin in type 2 diabetes mellitus. Perkovic V; Jardine M; Vijapurkar U; Meininger G Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163 [TBL] [Abstract][Full Text] [Related]
76. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]. Scheen AJ Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788 [TBL] [Abstract][Full Text] [Related]
77. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561 [TBL] [Abstract][Full Text] [Related]
78. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Elmore LK; Baggett S; Kyle JA; Skelley JW Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690 [TBL] [Abstract][Full Text] [Related]
79. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Tamborlane WV; Polidori D; Argenti D; Di Prospero NA Pediatr Diabetes; 2018 Jun; 19(4):649-655. PubMed ID: 29271103 [TBL] [Abstract][Full Text] [Related]
80. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]